Additionally, two posters will be presented on May 15, 2025, featuring research by Dr. Karol Budzik on engineered virus-like particles and Dr. Dylan Dautel on improving cargo loading in these particles.

Details about these presentations will be made available on nChroma's website following the event, showcasing their commitment to advancing genetic medicine.

The company employs a disease-first approach, integrating gene-regulating technologies with programmable in vivo delivery mechanisms to create effective treatments for high unmet medical needs.

nChroma Bio will showcase its innovative research at the 28th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT), taking place from May 13-17, 2025, in New Orleans, LA.

Melissa Bonner, PhD, nChroma's Chief Scientific Officer, expressed pride in their work being selected for presentation, emphasizing advancements in targeted non-viral delivery methods for in vivo genetic therapies.

One of the key presentations will be an oral session titled 'Efficient and Liver-Detargeted In Vivo Multiplex Gene Editing of Human Hematopoietic Stem and Progenitor Cells,' scheduled for May 14, 2025, presented by Dr. Pauline Schmit.

Among their developments, nChroma is focused on optimized genetic therapies, with their lead candidate, CRMA-1001, aimed at providing a functional cure for chronic hepatitis B.